EUVIMEDEUVIMED entdecken
Leserbrief

Hyper‐ CVAD Versus Hyper‐ CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis

Elias Jabbour, Hannah Goulart iD, Koji Sasaki iD, Caitlin R Rausch iD, Nitin Jain, Tapan M Kadia iD, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi iD, Guillermo Montalban-Bravo, Guillermo Garcia-Manero und 8 weitere

American Journal of Hematology · 2026-07 · 101 (7) · 1729-1736

DOI: 10.1002/ajh.70327 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 25.04.2026. Verfasst von Elias Jabbour und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit nennt 14 Literaturangaben. Gefördert von: NIH/NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

ALL—molecular diagnosis and therapyimmunotherapyleukemiastem cell transplantation

Autor:innen und Institutionen

  • Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Hannah Goulart, Koji Sasaki, Caitlin R Rausch, Tapan M Kadia, Farhad Ravandi, Danielle Hammond, Mahesh Swaminathan

Förderung

  • NIH/NCI

Zitieren

APA

Jabbour, E., Goulart, H., Sasaki, K., Rausch, C. R., Jain, N., Kadia, T. M., DiNardo, C., Daver, N., Pemmaraju, N., Ravandi, F., Montalban-Bravo, G., Garcia-Manero, G., Hammond, D., Swaminathan, M., Hachem, M., Khouri, R., Ohanian, M., Garris, R., Short, N. J., & Kantarjian, H. M. (2026). Hyper‐ CVAD Versus Hyper‐ CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis. American Journal of Hematology, 101(7), 1729-1736. https://doi.org/10.1002/ajh.70327

Vancouver

Jabbour E, Goulart H, Sasaki K, Rausch CR, Jain N, Kadia TM, et al. Hyper‐ CVAD Versus Hyper‐ CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis. American Journal of Hematology. 2026;101(7):1729-1736. doi:10.1002/ajh.70327

BibTeX
@article{Jabbour2026,
  author = {Jabbour, Elias and Goulart, Hannah and Sasaki, Koji and Rausch, Caitlin R and Jain, Nitin and Kadia, Tapan M and DiNardo, Courtney and Daver, Naval and Pemmaraju, Naveen and Ravandi, Farhad and Montalban-Bravo, Guillermo and Garcia-Manero, Guillermo and Hammond, Danielle and Swaminathan, Mahesh and Hachem, Maria and Khouri, Rita and Ohanian, Maro and Garris, Rebecca and Short, Nicholas J and Kantarjian, Hagop M},
  title = {Hyper‐ CVAD Versus Hyper‐ CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {7},
  pages = {1729--1736},
  doi = {10.1002/ajh.70327}
}
Kostenlos starten →